Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 20/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 18/20 | 0.56 |
| ▸ | DRD2 | P14416 | 14/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4770291 | 0.92 | DRD3 (0.57) | DRD3KCNH2DRD2HRH1HTR1A | |
| SCHEMBL4764981 | 0.90 | DRD3 (0.55) | DRD3KCNH2DRD2HRH1HTR1A | |
| SCHEMBL5098397 | 0.90 | DRD3 (0.51) | DRD3KCNH2DRD2 | |
| SCHEMBL5098581 | 0.89 | DRD3 (0.68) | DRD3KCNH2DRD2 | |
| SCHEMBL5112313 | 0.89 | DRD3 (0.60) | DRD3KCNH2DRD2HRH1HTR1A | |
| SCHEMBL4763714 | 0.89 | KDM4E (0.59) | DRD3KCNH2DRD2 | |
| SCHEMBL5101732 | 0.88 | ALDH1A1 (0.58) | DRD3KCNH2DRD2 | |
| SCHEMBL5099718 | 0.88 | ALDH1A1 (0.58) | DRD3KCNH2DRD2 | |
| SCHEMBL4774162 | 0.87 | DRD3 (0.54) | DRD3KCNH2DRD2HRH1 | |
| SCHEMBL5111894 | 0.85 | DRD3 (0.70) | DRD3KCNH2DRD2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429579-B2 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents) | SMITHKLINE BEECHAM, PLC (GB) | 2008-09-30 | — | — | US | disclosed |
| US-20040171606-A1 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) | SMITHKLINE BEECHAM PLC (GB) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171606-A1 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) | DRD3, DRD2, DRD1 | DRD3 1/4885KCNH2 272/4885DRD2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.